Attovia Therapeutics

Attovia Therapeutics focuses on creating a biotherapeutic pipeline in immune-mediated diseases and oncology. The company leverages Attobody™, Alamar Biosciences' novel dual-reengineered nanobody platform, which generates small-sized binders with low picomolar affinity, enhanced specificity, accelerated internalization, and rapid tissue penetration. Attovia’s lead program is an Attobody for the treatment of immune disorders. The company is currently advancing multiple programs and plans to initiate more discovery projects.